Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.

Abstract

BACKGROUND\nNeurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration.\n\n\nOBJECTIVES\nTo determine whether plasma and CSF NfL (1) associate with motor or cognitive status in Parkinson s disease (PD) and (2) predict future motor or cognitive decline in PD.\n\n\nMETHODS\nSix hundred and fifteen participants with neurodegenerative diseases, including 152 PD and 200 healthy control participants, provided a plasma and/or cerebrospinal fluid (CSF) NfL sample. Diagnostic groups were compared using the Kruskal-Wallis rank test. Within PD, cross-sectional associations between NfL and Unified Parkinson s Disease Rating Scale Part III (UPDRS-III) and Mattis Dementia Rating Scale (DRS-2) scores were assessed by linear regression; longitudinal analyses were performed using linear mixed-effects models and Cox regression.\n\n\nRESULTS\nPlasma and CSF NfL levels correlated substantially (Spearman r\xa0=\xa00.64, P\u2009<\u20090.001); NfL was highest in neurocognitive disorders. PD participants with high plasma NfL were more likely to develop incident cognitive impairment (HR 5.34, P\xa0=\xa00.005).\n\n\nCONCLUSIONS\nPlasma NfL is a useful prognostic biomarker for PD, predicting clinical conversion to mild cognitive impairment or dementia. © 2021 International Parkinson and Movement Disorder Society.